Venture Certified
| 혁신성장유형 | 2024-09-05 ~ 2027-09-04 | 20240905030009 | 2024-09-05 |
Revenue CAGR +81.0%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 8.0B | 7.3B | 2.4B |
| Operating Profit | -2.0B | -5.0B | -2.3B |
| Net Profit | -2.0B | -5.1B | -2.4B |
| Total Assets | 15B | 13B | 13B |
| Total Liabilities | 10B | 6.5B | 15B |
| Total Equity | 4.8B | 6.8B | -1.9B |
Capital Erosion: Total equity is negative or below 50% of capital stock
Operating Loss: Op. profit -2B
3 Consecutive Years of Net Loss
Debt Ratio Surge (+118pp YoY)
▲ 65.2%
▲ 45.3%
▲ 69.3%
▲ 164.2%
▼ 269.7%
| Name | Position | Role |
|---|---|---|
| 임종태 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "서울특별시 성동구",
"ceo_name": "임종태",
"certificate": [
{
"cert_number": "20240905030009",
"changes": "",
"disclosure_date": "2024-09-05",
"first_cert_date": "2024-09-05",
"no": "1",
"type": "혁신성장유형",
"valid_period": "2024-09-05 ~ 2027-09-04"
}
],
"company_name": "(주)케이엘엠바이오",
"corp_no": "110111-*******",
"financials": {
"2022": {
"capital_stock": 300000000,
"cost_of_sales": 166030000,
"current_assets": 608582000,
"current_liabilities": 1469745000,
"gross_profit": 78645000,
"net_income": -240099000,
"net_income_bs": -240099000,
"non_current_assets": 668002000,
"non_current_liabilities": 0,
"non_operating_expenses": 24499000,
"non_operating_income": 10140000,
"operating_profit": -225740000,
"revenue": 244675000,
"sga_expenses": 304385000,
"total_assets": 1276584000,
"total_equity": -193161000,
"total_liabilities": 1469745000
},
"2023": {
"capital_stock": 1700000000,
"cost_of_sales": 906660000,
"current_assets": 636946000,
"current_liabilities": 649088000,
"gross_profit": -180360000,
"net_income": -508707000,
"net_income_bs": -508707000,
"non_current_assets": 688702000,
"non_current_liabilities": 0,
"non_operating_expenses": 19579000,
"non_operating_income": 7957000,
"operating_profit": -497085000,
"revenue": 726300000,
"sga_expenses": 316725000,
"total_assets": 1325648000,
"total_equity": 676560000,
"total_liabilities": 649088000
},
"2024": {
"capital_stock": 1700000000,
"cost_of_sales": 621534000,
"current_assets": 823891000,
"current_liabilities": 1020052000,
"gross_profit": 180460000,
"net_income": -199019000,
"net_income_bs": -199019000,
"non_current_assets": 673702000,
"non_current_liabilities": 0,
"non_operating_expenses": 19696000,
"non_operating_income": 18538000,
"operating_profit": -197861000,
"revenue": 801994000,
"sga_expenses": 378321000,
"total_assets": 1497593000,
"total_equity": 477541000,
"total_liabilities": 1020052000
}
},
"industry": "그 외 기타 분류 안된 화학제품 제조업",
"investment": [],
"main_products": "인체조직,인체조직유래의료기기",
"phone": "02-6215-****",
"years": [
2024,
2023,
2022
]
}Data Quality: 8/10 | Primary Source: Venture System | Section Coverage: 7/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | Public Data | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Venture System | Collected |
| Officers | Public Data | Collected |
| Employment | Not Collected | Not Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| G2B Procurement | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |
| Venture System Detail | 2026-02-25 | Collected |